Led effort to successfully file SEC form S4 to merge with IMAC holdings NASDAQ (BACK)
· Digitized Accounting department moving from paperless to Bill.com.
· Successfully raised $4.0 Million to complete the merger which will take place in late 2023.
· Replaced CFO and Controller and filed all SEC documents on time.
· Successfully cut costs and renegotiated toxic contracts.
· Settled $100 million dollar lawsuit against the company for $87,000.

Successfully filed SEC form S1, with no review, to up-list the company early next year.
· Finalized reverse split to allow the company to have enough authorized capital to allow for up-list raise.
· Negotiated conversion of $12 million in preferred equity to common stock increasing the overall financial health of the balance sheet
· Successfully negotiated 83 non-convertible notes worth $8.5 Million, that have been in default since 2019, that will convert into Preferred stock upon uplist

At Adhera, we pride ourselves on identifying new uses for existing drugs and drug candidates, lowering risk while saving millions of dollars and years in development. We specialize in advancing these drugs for large areas of unmet medical need, maximizing the gap between expense and market opportunity. Some may call it brilliant; we call it…Innovation Reimagined
· Successfully restructured the Company that was insolvent and on the verge of bankruptcy
· Negotiated Department of Justice Liability from $1.4 Million dollars to $100,000.
· Acquired two new pharmaceutical assets for equity and royalty payments
· Raised $3.0 Million dollars for Corporate Clean up
· Negotiated A/P from $1.8 Million to $450,000.
· Negotiated terms to Up list company through a $20 Million dollar Financing to Nasdaq.
· The company has been current with all SEC filings.

THER Golden, CO
Theralink provides personalized medicine data for physicians and measures the activation state of key drug targets and signaling pathways for Biopharmas through its patented assays .
· Facilitated the successful merger of oncology diagnostic laboratory, Theralink, into the public company OncBioMune as both CEO & CFO
· Successfully oversaw the completion of the purchase of all Avant Diagnostics assets, handling all SEC and FINRA requirements
· Raised $1,075,000 in a private placement of Series C-2 Convertible Preferred Stock from two institutional investors, the Cavalry Fund and Lincoln Park Capital
· Championed rebranding under the name Theralink Technologies
· Investigated and reported product risks, fees, and performance statistics, identifying possible risks to shareholder agreements to drive value creation
· Negotiated successfully with OBMP creditors to enable a merger with Theralink
· Continue to consult on all aspects of CFO duties, including accounting, financial planning and analysis, tax, treasury, investor relations, and corporate strategy.
· Facilitate and collaborate with Theralink leadership to shape the financial and organizational strategy and implement post-transaction business models
· Drove value creation, navigating political and economic uncertainty
· As a BOD member I have assisted in guiding the company's inexperienced management into a position where the company will be listed on a senior exchange within the next 3 quarter.

OTCQB: OBMP Baton Rouge, LA
OncBioMune was a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient.
· Oversaw the financial and administrative processes for a publicly traded company
· Directed business development efforts including the expansion of operations to accommodate increased research and clinical development
· Responsible for human resources and operations management, treasury management and cash management, financial and accounting management, all banking and investor relationships, inventory management, and monthly close
· Successfully merged company with Avant Diagnostics, INC.

OTCQB: OBMP Baton Rouge, LA
· Successfully brought therapeutic cancer vaccine from the R&D stage to Phase 2 and completed the international acquisition of a medical distribution company.
· Successfully raised over $22 million dollars in both/equity financings and Department of Defense Financings.
· Handled all SEC and FINRA requirements to successfully bring Oncbiomune public
· Contributed to the administration of the three contracts that led to the clinical studies for the Company’s lead product, ProscaVax™
· Oversaw the Manufacturing of all products.
· Represented OncBioMune across various media outlets.
· Managed all governmental relationships (both Federal and State) including the Department of Defense, VA, Congressional Earmarks, Internal Revenue Service, State Department of Revenue, Natick, and the United States Navy

Financial services firm who specialized in Life Insurance, Annuities and Mutual Funds.
· Customized financial profiles for both individual and group clients.
· Performed detailed financial profiles to forecast and analyze prospective investments including life insurance, annuities, mutual funds and brokerage accounts.
· Collaborated with two sales teams, earning awards in GDC produced over the first year of the producer contract.